The Centre for the Commercialization of Antibodies and Biologics (CCAB) translates early stage biologics into high-value assets and products. We have an extensive portfolio of fully-human antibodies, discovered by the University of Toronto’s antibody R&D engine: the Toronto Recombinant Antibody Centre (TRAC).
Work with us to access world-class expertise in synthetic antibody discovery, state-of-the-art phage displayed libraries and proprietary screening technologies.
The CCAB is strengthening the Canadian drug development landscape by de-risking academic research and, together with investors or partners, further developing select therapeutic programs toward the clinic. In addition, we also offer a number of antibody reagents, tools, and technologies for licensing. Talk to our Business Development team to see how CCAB can find a custom solution to your company’s antibody needs.
Christine Misquitta leads the general administration and communications activities for CCAB. This includes coordinating outreach events and media on behalf of CCAB for both the scientific community and general public as well as the writing of large scale funding proposals and their management once awarded. In this role, she is also the primary liaison with government, industry, partners, and other academic organizations. Christine has a background in molecular biology and obtained her PhD at McMaster University in Hamilton.
The big guys are here to stay Next Post:
#BIO2017: EY report urges bio firms to embrace ‘value labs’